21:45 , Oct 12, 2018 |  BioCentury  |  Finance

Versant seizes the RNA moment

As the RNA space continues to heat up, Versant Ventures opted out of companies looking to modify RNA directly, and instead seeded and launched RNA epigenetics company Gotham Therapeutics. Versant co-led Gotham’s $54 million series A...
23:25 , Oct 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer; cancer Patient sample, cell culture and mouse studies suggest inhibiting the METTL3-EIF3H interaction could help treat lung and other cancers. In tumor samples from patients with lung adenocarcinoma or seven other cancers, levels...
23:17 , Oct 3, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: September 2018

New Therapeutic Targets and Biomarkers: September 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in September. Therapeutic targets are defined as any protein, gene or other molecule that...
13:56 , Sep 20, 2018 |  BC Extra  |  Preclinical News

RNA-modifying enzyme loops mRNA to increase oncogene translation

Boston Children's Hospital researchers showed interaction between a translation factor and RNA-modifying enzyme could enhance oncogene translation by circularizing mRNA, suggesting that disrupting the protein-protein interaction could help treat cancer. At least two companies -- Storm...
19:30 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Patient sample, cell culture and mouse studies suggest inhibiting METTL3 could help treat AML. In tumor samples from cancer patients, METTL3 expression was higher in AML tumors than in 32...
00:43 , Nov 28, 2017 |  BC Extra  |  Preclinical News

Researchers identify METTL3 as target for AML

In a paper published in Nature, researchers at the University of Cambridge and Storm Therapeutics Ltd. (Cambridge, U.K.) showed that methyltransferase like 3 (METTL3) promotes post-transcriptional regulation of gene expression in leukemia, suggesting the RNA-modifying...
18:16 , Oct 26, 2017 |  BC Innovations  |  Emerging Company Profile

Taking RNA epigenetics by Storm

Storm Therapeutics Ltd. is the first company to come out of the budding field of RNA epigenetics, and is targeting RNA-modifying enzymes for cancer. CEO Keith Blundy told BioCentury RNA-modifying enzymes fit into the landscape of...
20:03 , Apr 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting FTO or promoting METTL3 expression could help treat glioblastoma multiforme (GBM). In primary GBM stem cell-based assays of tumor formation, overexpression of METTL3 decreased growth and...
20:03 , Apr 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting FTO or promoting METTL3 expression could help treat glioblastoma multiforme (GBM). In primary GBM stem cell-based assays of tumor formation, overexpression of METTL3 decreased growth and...
08:00 , Mar 3, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Methyltransferase like 3 (METTL3); METTL14

Infectious disease INDICATION: HIV / AIDs Cell culture studies suggest inhibiting METTL3 or METTL14 could help treat HIV / AIDS. In HIV-infected human CD4+ T cells, shRNA targeting METTL3 or METTL14 decreased levels of HIV gp120 and...